P2Y12 platelet receptor

Class

P2Y12 receptor antagonist — Evategrel (CG-0255), a novel prodrug of clopidogrel's active metabolite with a different bioactivation route

Pathway

Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation, for ACS/recent MI/stroke/PAD

P2Y12 is a receptor on the surface of platelets that responds to adenosine diphosphate (ADP), a signaling molecule released when platelets and damaged blood vessels are activated. ADP binding to P2Y12 amplifies platelet activation and promotes the fibrinogen-mediated cross-linking of platelets into a stable clot. Blocking this receptor reduces platelets' ability to aggregate, which lowers the risk of pathological clot formation inside arteries. This mechanism is central to treating and preventing acute coronary syndromes, recent myocardial infarction, ischemic stroke, and peripheral arterial disease, conditions in which arterial clots restrict blood flow to the heart, brain, or limbs. Because platelet activation can be triggered by ADP release even when other activating pathways are already blocked, targeting P2Y12 is often used together with other antiplatelet approaches to achieve broader protection. Many drugs in this class are inactive prodrugs that must be converted in the body into an active metabolite capable of binding the receptor irreversibly, permanently disabling it for the remaining lifespan of that platelet. Differences in how a prodrug is bioactivated can influence how consistently and how quickly antiplatelet effect is achieved across different patients.